Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)

Antibody drug conjugates (ADCs), consisting of a cancer-specific antibody and cytotoxic payload, are shown to be a potent class of anticancer therapeutics, with enhanced therapeutic efficacy and reduced “off-target” side effects. However, the therapeutic window of ADCs is narrowed by problems such a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyun Jung, Sung, Ho Jin, Lee, Yul Min, Choi, Sun Il, Kim, Yun-Hee, Heo, Kyun, Kim, In-Hoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246698/
https://www.ncbi.nlm.nih.gov/pubmed/32384770
http://dx.doi.org/10.3390/ijms21093286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246698/
https://www.ncbi.nlm.nih.gov/pubmed/32384770
http://dx.doi.org/10.3390/ijms21093286

Ejemplares similares